期刊文献+

阿托伐他汀联用烟酸缓释片治疗冠心病合并高脂血症的疗效观察 被引量:8

暂未订购
导出
摘要 目的:研究阿托伐他汀联用烟酸缓释片治疗冠心病合并高脂血症的临床疗效及安全性。方法:入选60例冠心病合并高脂血症患者,随机分为2组即阿托伐他汀组和联合用药组,前者服用阿托伐他汀片,后者服用阿托伐他汀片联合烟酸缓释片,疗程均8周。服药前、服药4周及8周分别测定TC、TG、HDL-C、LDL-C值。结果:联合用药组降低LDL-C的能力优于阿托伐他汀组(P<0.05),升高HDL-C的能力明显优于阿托伐他汀组(P<0.01),降低TC的能力治疗8周后优于阿托伐他汀组(P<0.05)。其总有效率达96.7%,高于阿托伐他汀组86.7%(P<0.05)。无明显不良反应发生。结论:阿托伐他汀联合烟酸缓释片治疗冠心病合并高脂血症血脂达标率高,具有良好的临床疗效,安全性好。
出处 《心脑血管病防治》 2009年第3期201-203,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
基金 永康市科技局基金项目编号200827
  • 相关文献

参考文献10

  • 1徐亚平,陈文肖.阿托伐他汀治疗老年高胆固醇血症患者对胰岛素抵抗的影响[J].中华老年医学杂志,2003,22(4):247-247. 被引量:83
  • 2胡春松,魏云峰,胡大一.临床调脂治疗的阶梯和综合策略[J].中国新药与临床杂志,2006,25(8):625-628. 被引量:11
  • 3邓万俊.他汀类药物与其他药物的相互作用[J].中国新药与临床杂志,2006,25(2):131-136. 被引量:35
  • 4Ray JG,Gong Y,Sykora K,et al.Statin Use and Survival Outtcomes in Elderly Patients With Heart Failure[J].Arch Intem Med,2005,165:62-67.
  • 5王海安.动脉粥样硬化防治的新动向[J].井冈山医专学报,2002,9(4):60-61. 被引量:5
  • 6Gupta EK,Ito MK.Lovastatin and extended-release niacin combination product:the first drug combination for the management of hyperlipidemia[J].Heart Dis,2002,4(2):124-137.
  • 7Pieper JA.Overview of niacin formulations:differences in pharmacckimetics,efficacy,and safety[J].Am J Health Syst Pharm,2003,60(13 SuppI2):S9-14
  • 8Grundy SM,Cleeman JI,Merz CN,et al.National Heart,Lung,and Blood Institute; American College of Cardiology Foundation; American Heart AssoCiation.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ[J].Circulation,2004,110(2):227-239.
  • 9Scheen AJ,Kulbertus H.Clinical study of the momth.Reveral and Prove-it:confirmation of the concept "the lower,the better" for cholesterol therapy in patients with coronary heart disease[J].Rev Med Liege,2004,59(3):167-173.
  • 10Barter P.HDL:a recipe for longevity[J].Atheroscler Suppl,2004,5(2):25-31.

二级参考文献74

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2126
  • 2王轶娜.阿托伐他汀引起横纹肌溶解1例[J].中国新药与临床杂志,2005,24(10):837-838. 被引量:8
  • 3THOMPSON PD,CLARKSON P,KARAS RH.Statin-associated myopathy[J].JAMA,2003,289 (13):1681-1690.
  • 4DAVIDSON MH.Controversy surrounding the safety of cerivastatin[J].Expert Opin Drug Saf,2002,1 (3):207-212.
  • 5STAFFA JA,CHANG J,GREEN L.Cerivastatin and reports of fatal rhabdomyolysis[J].N Engl J Med,2002,346(7):539-540.
  • 6RATZBRAVO AE,TCHAMBAZ L,KRAHENBUHL-MELCHER A,et al.Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy[J].Drug Saf,2005,28 (3):203-275.
  • 7BELLOSTA S,PAOLETTI R,CORSINI A,et al.Safety of statins:focus on clinical pharmacokinetics and drug interactions[J].Circulation,2004,109(23 Suppl 1):Ⅲ 50-Ⅲ 57.
  • 8KAJINAMI K,TAKEKOSHI N,SAITO YL.Pitavastatin:efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor[J].Cardiovasc Drug Rev,2003,21 (3):199-215.
  • 9McKENNEY JM.Efficacy and safety of rosuvastatin in treatment of dyslipidemia[J].Am J Health Syst Pharm,2005,62(10):1033-1047.
  • 10THOMPSON PD,LARKSON P,KARAS RH.Statin-associated myopathy[J].JAMA,2003,289 (13):1681-1690.

共引文献123

同被引文献38

引证文献8

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部